Evidence of angiogenesis in bronchial biopsies of smokers with and without airway obstruction  by Calabrese, Cecilia et al.
ARTICLE IN PRESSRespiratory Medicine (2006) 100, 1415–14220954-6111/$ - s
doi:10.1016/j.r
Correspondi
E-mail addrEvidence of angiogenesis in bronchial biopsies of
smokers with and without airway obstruction
Cecilia Calabresea,, Vincenzo Bocchinob, Alessandro Vatrellac,
Carlo Marzoa, Carmine Guarinoa, Sergio Mascittia, Carmelindo
M.E. Tranfaa, Mario Cazzolad, Pietro Michelie, Mario Caputia,
Serafino A. MarsicoaaDepartment of Cardio-Thoracic and Respiratory Sciences, Second University of Naples,
Monaldi Hospital, Via Bianchi, 80131 Naples, Italy
bRespiratory Sub Intensive Care Unit, Monaldi Hospital, Via Bianchi, 80131 Naples, Italy
cDepartment of Clinical and Experimental Medicine, University Federico II, Monaldi Hospital,
Via Bianchi, 80131 Naples, Italy
dDepartment of Respiratory Medicine, Cardarelli Hospital, Via Cardarelli 9, 80131 Naples, Italy
eDepartment of Pathology, Cotugno Hospital, Via Quagliariello 54, 80131 Naples, Italy
Received 13 October 2005; accepted 11 November 2005KEYWORDS
COPD;
Angiogenesis;
Smoke;
Vascular endothelial
growth factor;
Integrin avb3ee front matter & 2005
med.2005.11.009
ng author. Tel.: +39 081
ess: cecilia.calabrese@Summary The involvement of bronchial vasculature in the airway remodelling
occurring in symptomatic smokers with normal lung function and with chronic
obstructive pulmonary disease (COPD) has been poorly investigated.
An immunohistochemical study was performed on bronchial biopsies taken from 8
non-smokers and 18 smokers divided, according to global health initiative on
obstructive lung diseases (GOLD) classification of COPD, into two groups, GOLD 0 and
GOLD 2, each of 9 subjects. The number of vessels and the percentage of vascular
area in the lamina propria were evaluated by mAb anti-collagen IV. Cellular
expression of VEGF and vascular expression of avb3 integrin were evaluated by the
specific monoclonal antibodies. An image processing and analysis system was used to
quantify the immunohistochemical data.
The number of vessels, the vascular area, the cellular expression of VEGF, the
number and percentage of avb3 positive vessels were significantly higher in GOLD 0
and in GOLD 2 smokers than in non-smokers. The comparison between GOLD 0 and
GOLD 2 smokers did show a weak but significantly lower number of vessels in GOLD 2,
while the vascular area and the percentage of avb3 positive vessels did not differ
between the two groups. A higher cellular VEGF expression was detected in the
GOLD 2 than in the GOLD 0 group.Elsevier Ltd. All rights reserved.
7062365; fax: +39 081 5463812.
unina2.it (C. Calabrese).
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C. Calabrese et al.1416Angiogenesis of bronchial vessels is a component of the airway remodelling
occurring in symptomatic smokers with normal lung function and with COPD, it
seems independent by the development of airway obstruction and not related to its
severity.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Cigarette smoking represents the most important
risk factor of chronic obstructive pulmonary disease
(COPD) although only a minority of smokers devel-
ops airway obstruction. In COPD the inflammatory
process is associated with airway remodelling
characterized by goblet cell hyperplasia, squamous
metaplasia, submucosal gland and smooth muscle
hypertrophy, mucous plugging in the lumen, and
airway wall fibrosis.1 The remodelling process
results in thickening of the airway wall that is
strongly associated with the progression of COPD.2
Some features of airway remodelling in COPD, such
as the epithelial and glandular changes, are already
detectable in symptomatic smokers without estab-
lished airflow limitation. To date, the involvement
of the bronchial vascular component in airway
remodelling occurring in symptomatic smokers with
normal lung function and with COPD has been
poorly investigated.
Angiogenesis, the proliferation of new capillary
blood vessels from pre-existing blood vessels, has
been shown in several chronic airway inflammatory
diseases. Bronchiectasies are the most common
pulmonary condition associated with angiogenesis
of bronchial vessels.3 In bronchial asthma the
vascularity of the airways is increased and corre-
lates with the severity of the disease.4,5
Pathological angiogenesis has also been de-
scribed as a feature of several tobacco-related
diseases, in particular neoplasies.6 Lung cancer
growth and invasiveness seem to depend on
angiogenesis.7 Angiogenic squamous dysplasia has
been recognized as a preneoplastic lesion of lung
cancer.8
Angiogenesis is a multi-step process that is highly
regulated by various growth factors, adhesion
molecules and cytokines.
Vascular endothelial growth factor (VEGF) is the
most potent and widely distributed angiogenic
factor known to date.9 It is produced by different
cell types and acts specifically on endothelial cells
via tyrosine kinase receptors. It is involved in many
distinct aspects of angiogenesis, including prolif-
eration, migration, specialization and survival of
endothelial cells.Integrin avb3 is an adhesion molecule that is not
expressed or only expressed at low levels on resting
endothelium whereas it is upregulated in new
capillaries proliferating in response to angiogenic
stimuli. Integrin avb3 allows endothelial cells to
interact with a variety of extracellular matrix
components; in this way, vascular cells are able to
migrate to virtually all tissues.10 avb3 over expres-
sion has been shown in several human carcinoma
and vascular disorders.11 In mild to moderate
atopic asthmatics avb3 expression is increased in
the bronchial vasculature.12 Interestingly, recent
studies suggest that VEGF and avb3 may collaborate
to regulate vessel formation.13,14
In order to evaluate whether an angiogenic
process occurs in the airways of symptomatic
smokers with and without COPD we investigated,
by immunohistochemistry, in the lamina propria of
bronchial mucosa: (1) the number of bronchial
vessels and the percentage of vascular area; (2) the
number of VEGF positive cells; (3) the number of
integrin avb3 positive vessels.Methods
Subjects
We recruited 8 healthy non-smokers and 18 smokers
divided, according to global health initiative on
obstructive lung diseases (GOLD) classification, into
two groups: 9 subjects with symptoms of chronic
bronchitis and with normal lung function (GOLD 0),
and 9 subjects with symptoms of chronic bronchitis
and with moderate COPD (GOLD 2).15 The char-
acteristics of the study populations are summarized
in Table 1.
All smokers had a history of cigarette smoking
equivalent to at least 20 pack-years. They had no
CT evidence of emphysema and they were not
treated with inhaled or oral corticosteroids on a
regular basis. Both smokers and non-smokers were
not atopics, as proven by negative skin tests for
common allergens. None was affected by lung
cancer or other malignancy.
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Table 1 Characteristics of subjects.
Non-
smokers
(n ¼ 8)
GOLD 0
(n ¼ 9)
GOLD 2
(n ¼ 9)
M:F 6:2 8:1 8:1
Age, yr 56 (4.6) 50 (3.6) 59 (3.2)
Smoking history
(pack-years)
— 41 (9) 48 (8.2)
FEV1 (%
predicted)
101 (4.3) 104 (5.1) 62 (3.1)
FEV1/FVC (%) 82 (1) 80 (2.3) 62 (3)
Data shown as mean (SE) values.
GOLD 0: symptomatic smokers with normal lung function;
GOLD 2: symptomatic smokers with moderate COPD;
FEV1: forced expiratory volume in 1 s, FVC: forced vital
capacity.
Angiogenesis in smokers with and without COPD 1417The study conformed to the declaration of
Helsinki and written informed consent was ob-
tained from each subject.
Fiberoptic bronchoscopy
Fiberoptic bronchoscopy was performed as pre-
viously described.16 Subjects were pre-medicated
intramuscularly with 0.5mg atropine sulphate and
10mg diazepam, 30min before the procedure.
Local anaesthesia was obtained by 2% lignocaine,
15min before bronchoscopy. An additional aliquot
of 2% lignocaine was applied topically to the
pyriform sinuses and vocal cords to prevent cough-
ing and as a local anaesthesia. No other drugs were
administered before or during bronchoscopy.
Fiberoptic bronchoscope was introduced through
the nose or transorally (Olympus BF, Type 1T 250;
Olympus Optical Co., Tokyo, Japan). Using alligator
forceps at least 2 mucosal biopsy specimens were
taken from the subcarinae in the middle and lower
lobes of the right lung.
Processing of bronchial biopsies and staining
procedure
Mucosal biopsies were immediately transferred into
ice-cooled acetone, containing the protease inhi-
bitors iodoacetamide (20mM) and phenylmethyl-
sulphonylfluoride (PMSF) (2mM) for fixation, stored
at 20 1C for 24 h, and then processed into the
water-soluble resin, glycolmethacrylate (GMA)
resin (Polysciences, Northampton, UK) for
embedding.
Two-micrometer sections were cut by ultrami-
crotomy, floated on 0.2% (v/v) ammonia solutionfor 1min, picked up onto poly L-lysine-coated
slides, and dried at room temperature for 1–4 h.
Mouse monoclonal antibodies (mAbs) directed
against human collagen IV (1:100, M0785, DAKO),
to quantify the blood vessels within the lamina
propria, human VEGF121, 165, 189 (1:25, MS-1467,
Neomarkers) and human integrin av/b3 (1:10,
23C6, Santa Cruz Biotechnology, Inc.) were used
as primary antibodies.
Immunostaining applied to GMA-embedded tissue
has been previously described.17 Slides were pre-
treated with a solution of 0.1% (w/v) sodium azide
and 0.3% (v/v) hydrogen peroxide for 30min to
inhibit endogenous peroxidase activity. After three
5-min washes in tris-buffered saline (TBS) pH 7.6,
blocking medium, consisting of Dulbecco’s modified
Eagle’s medium, 10% foetal calf serum, and 1%
bovine serum albumin, was applied for 30min.
Sections were then incubated with the primary
antibody for 16–20 h overnight at room tempera-
ture. After overnight incubation, sections were
washed in TBS. Bound antibodies were then
labelled with biotinylated anti-mouse IgG (Vector
Laboratories, CA, USA) during a 2-h incubation and
made visible using a streptavidin–biotin–horsera-
dish–peroxidase complex detection system (Dako,
Glostrup, DK). Aminoethylcarbazole was applied as
chromogen, resulting in a red reaction product.
Sections were counterstained with Mayer’s haema-
toxylin. Appropriate control sections were similarly
treated either with the primary antibody omitted
or replaced by an unrelated mouse mAb.Assessment and quantification of immuno-
histochemical staining
Sections were coded so that the observers were
unaware of the clinical details of the case under
study. An image processing and analysis system
(LEICA IM50, LEICA Cambridge Ltd., Cambridge, UK)
was used to quantify immunohistochemical data in
the lamina propria. The lamina propria, a zone
150 mm deep in the bronchial mucosa along the
length of the epithelial basement membrane, was
outlined by hand on the colour monitor using an
electronic mouse cursor.
Collagen IV positively stained vessels were
counted in the lamina propria and were then
divided by the lamina propria area examined to
determine the number of vessels per square
millimetre of lamina propria. All structures internal
to the vessel endothelial basement membrane were
evaluated as vascular area. The percentage of
vascular area was determined by dividing the
vascular area by the total area of lamina propria.
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C. Calabrese et al.1418The mean size of vessels was estimated by dividing
the total vascular area by the total number of
vessels for each subject.
The analysis system was also used to carry out
comparison of sequential sections. Collagen IV
immunoreactivity in the lamina propria was paired
with adjacent sections separately stained for
integrin avb3 to enable avb3 staining to be
localized to specific collagen IV positive vessels.
Results were expressed either as number of avb3
positive vessels per square millimetre of lamina
propria either as the percentage of avb3 positive
vessels per collagen IV positive vessels. Further-
more, the number of VEGF positively stained cells
was counted in the entire lamina propria. Results
are expressed as the number of VEGF positive cells
per square millimetre of lamina propria.
Statistical analysis
Group data were expressed as mean (SE) or median
(range) when appropriate. Differences between
groups were analysed using analysis of variance
(ANOVA) followed by unpaired Student’s t-test for
clinical data and the Kruskall–Wallis test followed
by Mann–Whitney U test for morphological data.
Correlation coefficients were obtained by Spear-
man’s rank-order method. In all cases a value of
Po0:05 was considered significant.Results
Clinical data
The sex ratio and the age of subjects were similar
between the non-smokers, GOLD 0 and GOLD 2
groups. No statistically significant difference in the
smoking history was observed between GOLD 0 and
GOLD 2 smokers. As expected, GOLD 2 smokers had
a significantly lower forced expiratory volume in 1 s
(FEV1) expressed as % of predicted value and FEV1/Table 2 Immunohistochemical data.
Non-smokers (n ¼ 8)
Vessels/mm2 143 (32–196)
Vascular area (%) 5.3 (3.3–7.9)
Mean vessel area (mm2) 416 (251–670)
VEGF+cells/mm2 9.2 (0–21)
avb3+vessels/mm2 9.6 (0–19)
avb3+vessels (%) 6.2 (0–11)
Data shown as median (range) values.
GOLD 0: symptomatic smokers with normal lung function; GOLD 2forced vital capacity (FVC) (%) than GOLD 0 and
non-smokers (Po0:0001) (Table 1).Immunohistochemical findings
Immunohistochemical data are reported in Table 2.
The number of collagen IV+ vessels and the
percentage of vascular area were significantly
higher in GOLD 0 (Po0:0001; P ¼ 0:03, respec-
tively) and in GOLD 2 (P ¼ 0:02; P ¼ 0:01, respec-
tively) compared to non-smokers; GOLD 0 smokers
had a higher number of collagen IV+ vessels than
GOLD 2 (P ¼ 0:04) while no significant difference
was detected in the percentage of vascular area
(Figs. 1A and B and 2A and B). The mean vessel area
was not significantly different between the three
groups.
VEGF staining was localized in the bronchial
epithelium, on airways smooth muscle cells, in the
bronchial microvasculature of the mucosa and
submucosa, and on inflammatory cells in all
subjects. The number of VEGF+cells were signifi-
cantly higher in GOLD 0 (P ¼ 0:003) and in GOLD 2
(Po0:0001) compared to non-smokers. A signifi-
cantly higher number of VEGF+cells was also
observed in GOLD 2 compared to GOLD 0
(P ¼ 0:03) (Figs. 1C and 3).
The number and the percentage of avb3+vessels
were significantly higher in GOLD 0 and in GOLD 2
compared to non-smokers (P ¼ 0:02). There were
no significant differences in the number and
percentage of avb3+vessels between GOLD 0 and
GOLD 2 (Figs. 1D and 4A and B)Relationship between immunohistochemical
and clinical/functional data
No correlations between the immunohistochemical
and clinical/functional data were observed.GOLD 0 (n ¼ 9) GOLD 2 (n ¼ 9)
281 (202–459) 201 (128–373)
8.4 (4.9–17.7) 7.9 (6–12.2)
328 (161–477) 412 (292–803)
149 (39–51) 252 (109–474)
76 (0–184) 60 (0–196)
28 (0–91) 29.8 (0–80)
: symptomatic smokers with moderate COPD.
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Figure 1 Immunohistochemistry. Photomicrographs showing bronchial biopsy specimens immunostained with (Panel A)
mAb anti-collagen IV in a non-smoker, (Panel B) mAb anti-collagen IV in a smoker, (Panel C) mAb anti-VEGF in a smoker
(Panel D) mAb anti-avb3 integrin in a smoker. Panels B–D are serial sections of the same specimen. Scale bar ¼ 20 mm.
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Figure 2 Bronchial vascularity. (A) Number of vessels/mm2 of lamina propria and (B) percentage of vascular area in the
lamina propria in non-smokers, symptomatic smokers with normal lung function (GOLD 0) and symptomatic smokers
with moderate COPD (GOLD 2). Horizontal bars represent the median.
Angiogenesis in smokers with and without COPD 1419Discussion
The present study shows that in the central airways
of symptomatic smokers with normal lung function
(GOLD 0) and with moderate COPD (GOLD 2) thereis an increase in bronchial vascularity, expressed in
terms of both number of vessels and vascular area,
compared to healthy non-smokers. The increase in
bronchial vasculature is associated with higher
vascular expression of avb3 integrin and cellular
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C. Calabrese et al.1420expression of VEGF. These results suggest that an
angiogenic process occurs in the airways of sympto-
matic smokers with normal lung function and in
those with moderate COPD.
The study also indicates that angiogenesis of
bronchial vasculature is not related to airway
obstruction; in fact, when we compared GOLD 2
and GOLD 0 groups, we found a weak but
significantly lower (P ¼ 0:046) number of vessels
in GOLD 2, while the vascular area and theα
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Figure 4 Vascular expression of avb3 integrin. (A) Number of
of avb3+vessels/mm2 of lamina propria in non-smokers, symp
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Figure 3 Cellular expression of VEGF. Number of VEGF+-
cells/mm2 of lamina propria in non-smokers, sympto-
matic smokers with normal lung function (GOLD 0) and
symptomatic smokers with moderate COPD (GOLD 2).
Horizontal bars represent the median.percentage of actively proliferating avb3 positive
vessels did not differ between the two groups.
Few quantitative studies on bronchial vascula-
ture have been performed in smokers with and
without airway obstruction and all of them have
analysed specimens obtained from subjects af-
fected or at high risk for lung cancer, a disease in
which angiogenesis is a major feature in both the
invasive and preinvasive lesions. In contrast with
our data, Kuwano et al.,18 using a Masson’s
trichrome stain, did not find a higher number of
vessels and vascular area in COPD; however, when
they performed immunohistochemistry with factor
VIII antibody on three cases they found a consider-
ably higher number of vessels in COPD. In the
present study we utilized monoclonal antibodies
against collagen IV that outlines the basal lamina
around vessels, to specifically identify the vascu-
lature. Moreover, the GMA embedding technique
provides an excellent morphology allowing the
clear distinction of collagen IV+vessels from other
positively stained structures. Consistent with our
results, Hiroshima et al.,19 in bronchial biopsies
obtained from smokers with sputum cytology
suspicious or positive for malignancy, detected an
increased number of bronchial vessels compared to
non-smokers. This change was present in appar-
ently normal mucosa as well as in hyperplastic
lesions, squamous metaplasia or dysplasia. More
recently, Hashimoto et al.20 found that the vascu-
larity of medium and small airways was greater in
patients with COPD compared to normal subjects.
However, the difference reached the statistical
significance only in the percentage of vascularity in
the small airways.Non smokers GOLD 0 GOLD 2
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Angiogenesis in smokers with and without COPD 1421In the present study we found an increase in
cellular VEGF expression in GOLD 0 and GOLD 2
smokers compared to non-smokers. Our results are
consistent with those of Kanazawa et al.21 who
found increased VEGF levels in the induced sputum
of patients with chronic bronchitis and Kranenburg
et al.22 who demonstrated higher expression of
VEGF in central and peripheral airways of ex-
smokers with COPD than in those without COPD. In
our study VEGF expression was higher in GOLD 2
than in GOLD 0 group although, in contrast with the
two previous studies, it did not correlate with the
degree of airway obstruction. The role of VEGF in
the pathogenesis of COPD seems to be controver-
sial; it has been hypothesed that VEGF plays a
detrimental function in the bronchi and a protec-
tive role in the alveoli.23 Recently, Nagay et al.24
reported decreased VEGF expression in alveolar
macrophages of long-term smokers with and with-
out emphysema. The decrease of VEGF in the lower
respiratory tract may lead to impaired structure
homeostasis in the lung and emphysema develop-
ment. This hypothesis is also supported by in vitro
and in vivo studies showing that reduced VEGF
levels or blockade of VEGF receptors could play a
role in the pathogenesis of emphysema.25,26 In the
present study all COPD subjects did not have any
HRCT scan or functional evidence of emphysema.
The expression of integrin avb3 on bronchial
blood vessels of symptomatic smokers with and
without COPD has never been investigated. An
increased avb3 expression has been well documen-
ted on tumour-associated vessels, in the wound
repair process and in some other vascular disor-
ders.11,27,28 Furthermore, increased avb3 expres-
sion has been documented on the bronchial
vasculature in mild to moderate atopic asth-
matics.12 A recent study suggests that VEGF and
avb3 integrin synergistically exert angiogenic ef-
fects although their mechanisms of cross-talk are
not well defined. It has been hypothesized a
physical interaction between VEGFR and the avb3
integrin and/or the involvement of a common
downstream intracellular signalling pathway.14
The increased avb3 expression on bronchial vessels
associated to the higher VEGF expression suggests
that these two molecules could cooperate in the
angiogenetic process occurring in the airways of
symptomatic smokers with normal lung function
and with COPD.
The role of angiogenesis of bronchial vessels in
the pathogenesis of the inflammatory and remodel-
ling process occurring in smokers with and without
airway obstruction has to be clarified. Angiogenesis
of bronchial vasculature could increase the recruit-
ment of inflammatory cells and the exudation ofmediators in the airways. In animal models of
chronic airway inflammation, angiogenesis and
microvascular remodelling resulted not only in
more or larger blood vessels but also in functionally
abnormal blood vessels mediating sustained leak-
age and leukocyte adhesion.29,30 It has also been
demonstrated that in patients with COPD bronchial
vessels are activated as assessed by an increased
vascular expression of E-selectin.31 Moreover, it
cannot be excluded that the increase in the
vascular area and vessel numbers was also due to
the thickening and elongation of existing vessels as
the results of the study of Tormanen in OVA
sensitized mice could suggest.32 However, the
associated increased expression of VEGF and avb3
revealed in this paper indicate that a proliferation
of new vessels occurs.
Bronchial vessel proliferation, through the thick-
ening of the airway wall, could also be involved in
the pathogenesis of airway obstruction. However,
in the present study we did not find any difference
in the percentage of vascular area between
smokers with normal lung function and those with
moderate COPD. This finding could be explained by
the fact that we investigated the central airways
while the more peripheral airways seem to be
involved in the increased resistance in COPD.
In conclusion, the present study shows that
angiogenesis of bronchial vessels is a component
of airway remodelling occurring in symptomatic
smokers with and without COPD, is independent by
the development of airway obstruction and not
related to its severity.Acknowledgements
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